In This Article:
BellRing Brands (BRBR) closed at $68.10 in the latest trading session, marking a +1.19% move from the prior day. The stock exceeded the S&P 500, which registered a gain of 0.49% for the day. At the same time, the Dow lost 0.2%, and the tech-heavy Nasdaq gained 1.22%.
Coming into today, shares of the nutritional supplements company had lost 11.63% in the past month. In that same time, the Medical sector lost 1.05%, while the S&P 500 lost 8.15%.
The upcoming earnings release of BellRing Brands will be of great interest to investors. The company's earnings per share (EPS) are projected to be $0.52, reflecting a 15.56% increase from the same quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $574.59 million, reflecting a 16.17% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.25 per share and a revenue of $2.31 billion, representing changes of +16.58% and +15.75%, respectively, from the prior year.
Any recent changes to analyst estimates for BellRing Brands should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.67% higher within the past month. At present, BellRing Brands boasts a Zacks Rank of #2 (Buy).
Digging into valuation, BellRing Brands currently has a Forward P/E ratio of 29.97. This expresses a premium compared to the average Forward P/E of 18.22 of its industry.
We can additionally observe that BRBR currently boasts a PEG ratio of 2.02. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Products stocks are, on average, holding a PEG ratio of 2.02 based on yesterday's closing prices.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 130, positioning it in the bottom 49% of all 250+ industries.